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Introduction 
Oral corticosteroid treatment of allergic bronchopul- 
monary aspergillosis (ABPA) prevents the bronchial 
environment from being hospitable to Aspergillus by 
inhibiting harmful immunologic reactions. Despite these 
benefits of corticosteroids, it is widely known that they 
have long-term side-effects. Itraconazole is a new oral 
triazole antifungal agent with low toxicity that is active 
against Aspevgillus spp. in vitro as well as in vivo (1). The 
present authors administered itraconazole monotherapy in 
a young woman with ABPA. The symptoms, signs, partial 
atelectasis and laboratory findings improved after 6 
weeks. Although she experienced two mild relapses, the 
symptoms subsided without corticosteroid therapy. She 
has been taking itraconazole for 20 months, and no 
adverse effects have been observed. 
Case Report 
As 23-year-old woman (height 160 cm, weight 80.9 kg) had 
had bronchial asthma since childhood. At the age of 19 
years (May 1990), the patient was admitted to the hospital 
for the first time with wheezing and abnormalities in chest 
radiographs. Chest radiography and chest computed tom- 
ography (CT) showed proximal sacculated bronchiectasis 
and infiltrates in the left lower lobe. Laboratory findings 
showed eosinophilia in the peripheral blood (1584 mm- 3, 
and elevated serum levels of total IgE (11 000 U ml - I). 
Serum IgG precipitins to Aspergillus and an immediate skin 
test for A. fumigatus antigen were positive (21 x 22 mm), 
and delayed skin reactivity was observed (35 x 65 mm). 
Sputum cultures revealed the growth of A. jiimigatus. In the 
pulmonary function test, FEV,., was reduced to 65%. 
Based on these findings, ABPA was diagnosed. The patient 
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was treated with prednisone (40 mg) for 4 weeks in July 
1990. Her signs, symptoms and chest radiographs, as well 
as total IgE serum levels (5194 U/ml) and FEV,.,, 
improved (74%). After prednisone treatment, she did 
not experience bronchial asthma and did not require 
hospitalization. 
At the age of 23 years (July 1994), the patient devel- 
oped mild dyspnoea and rhonchi and returned to the 
authors’ hospital. Chest radiography and CT showed 
partial atelectasis of the right upper lobe and infiltration 
of the left lower lobe [Plate l(a)]. High total IgE levels 
(8990 U ml ~ I), eosinophilia (1154 mm ~ 3, and positive 
serum Aspergillus precipitins were found. In the pul- 
monary function test, FEV,.,, was reduced to 53%. 
Bronchofiberscope findings showed oedema of the right 
upper lobe orifice and narrowing of the right B3 bron- 
chus. Aspergillus spp. were cultured from the secretion 
collected from the B3 bronchus. Although the authors 
wished to administer oral prednisone, the patient strongly 
refused it because of the accompanying increase in appe- 
tite and body weight. Thus, the authors administered 
100 mg day- ’ (1.24 mg kg- ’ day- ‘) of itraconazole 
alone, and the rhonchi disappeared after 2 weeks. Lab- 
oratory findings showed a decrease in eosinophilia 
(563 mm ~ 3, and in the total IgE level (4314 U ml ~ I). 
Chest radiography revealed improvement after 6 weeks. 
Bronchofiberscope findings showed improvement in the 
narrowing of the right upper bronchus, and no fungus 
was cultivated from the pulmonary secretion. The patient 
experienced two mild relapses after administration. The 
first relapse occurred in October 1994 because she had not 
taken itraconazole on a regular basis. The authors 
stressed the need for her to take itraconazole 100 mg 
day- ’ regularly and remission occurred after 6 weeks 
[Plate l(b)]. The second relapse occurred in May 1995. 
The dose of itraconazole was increased to 150 mg day- ’ 
(1.95 mg kg ~ ’ day - ‘), and remission occurred after 4 
weeks. She did not receive inhaled steroids during these 
periods. The authors plan to reduce the dose of itracona- 
zole according to the signs, symptoms and laboratory 
findings. If she experiences severe relapse, oral or inha- 
lational corticosteroid therapy will be administered with 
her permission. She has been taking itraconazole for 20 
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PLATE 1. Chest computed tomography (CT) performed in July 1994 showed mucoid impaction in the proximal ectasic 
bronchus and partial atelectasis of the right upper lobe (a). Chest CT performed in December 1994 revealed partial 
atelectasis of the right upper lobe and proximal saccular bronchiectasis (b). 
months, and no relapse, no liver dysfunction or other 
adverse effects have been seen. 
Discussion 
Oral corticosteroids have been widely used for the treat- 
ment of ABPA, both for prevention of repeated episodes 
and for decreasing the likelihood of permanent damage. 
They suppress the allergic responses and inflammation 
associated with the heavy colonization of Aspergillus in 
the airways (2). Antifungal agents have proven unsuccess- 
ful at eradicating heavy colonization in the airways. Shale 
et al. reported a l-year study of the efficacy of ketocona- 
zole in non-invasive pulmonary aspergillosis (3). This 
pilot study has shown benefits from the use of ketocona- 
zole and suggests that further studies of its use in ABPA 
may be warranted. Itraconazole, a new oral triazole with 
low toxicity, is active against Aspergillus spp. in vitro and 
in vivo (1). The activity of itraconazole against Aspergillus 
spp. is more than that of ketoconazole. Based on the 
pathogenesis of ABPA, the authors believed that the 
administration of itraconazole would eliminate Aspergil- 
lus in the airways and reduce the allergic responses in 
ABPA. 
Several cases of ABPA treated with itraconazole have 
been reported (4). Most of these patients were treated 
with doses of more than 100 mg day- ‘. Denning et al. 
reported the cases of six patients, three with cystic fibro- 
sis, treated with itraconazole 400 mg day- ’ for l-7 
months (5). The mean oral corticosteroid dose was 
reduced in these cases. One patient suffered acute ABPA 
after itraconazole treatment was stopped. The present 
authors did not treat with dose of more than 200 mg 
day ~ i because 100-200 mg day- ’ of itraconazole can be 
used in Japan. 
The indication of itraconazole monotherapy for ABPA 
has not been approved because only a small number of 
patients have been treated with itraconazole monotherapy. 
This case suggested that itraconazole monotherapy might 
be a useful tool against ABPA. 
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